循环miRNA在肝细胞癌治疗及预后评估中的研究进展

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (621 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肝细胞癌（HCC）是常见的恶性肿瘤之一，具有较高的致死率，HCC的早期有效诊断至关重要。微小RNA（miRNA）参与肝癌细胞增殖、分化、迁移、新生血管生成、细胞凋亡等活动过程，有望成为协助肝癌的诊断、治疗及预后判断的新生生物标志物。本文主要将血清或血浆的miRNA在肝癌临床应用中的研究进展作一综述，旨在为肝癌的临床诊断、治疗以及评估肝癌的预后提供新思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨益波余保平

关键词 ：微小RNA, 肝细胞癌, 早期检测, 治疗, 预后

Abstract：Hepatocellular carcinoma (HCC) was one of the common malignant tumors with a high mortality rate. Early and effective diagnosis of HCC was essential. MicroRNA (miRNA) was involved in the proliferation, differentiation, migration, neovascularization, apoptosis and other activities of liver cancer cells, which was expected to become new biomarkers to assist in the diagnosis, treatment and prognosis of liver cancer. This article mainly reviews the research progress of serum or plasma miRNA in the clinical application of liver cancer, and aimed to provide new ideas for the clinical diagnosis, treatment and evaluation of liver cancer prognosis.

Key words： MicroRNA Hepatocellular carcinoma Early detection Treatment Prognosis

基金资助:国家自然科学基金资助项目（81770638）。

通讯作者: 余保平（1962.7-），男，博士，教授，博士生导师；研究方向：胃肠动力，内脏痛。

作者简介: 杨益波（1991.8-），男，武汉大学第一临床学院2017级消化内科专业在读硕士研究生；研究方向：内脏痛，胃肠动力。

引用本文:

杨益波余保平. 循环miRNA在肝细胞癌治疗及预后评估中的研究进展[J]. 中国医药导报, 2020, 17(16): 45-48.
YANG Yibo YU Baoping. Research progress of circulating miRNA in the treatment and prognosis of hepatocellular carcinoma. 中国医药导报, 2020, 17(16): 45-48.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I16/45

[1] Villanueva A. Hepatocellular Carcinoma [J]. N Engl J Med，2019，380（15）：1450-1462.
[2] Duran SR，Jaquiss RDB. Hepatocellular Carcinoma [J]. N Engl J Med，2019，381（1）：e2.
[3] Couri T，Pillai A. Goals and targets for personalized therapy for HCC [J]. Hepatol Int，2019，13（2）：125-137.
[4] Hao NB，He YF，Li XQ，et al. The role of miRNA and lncRNA in gastric cancer [J]. Oncotarget，2017，8（46）：81572-81582.
[5] Morales S，Monzo M，Navarro A. Epigenetic regulation mechanisms of microRNA expression [J]. Biomol Concepts，2017，8（5-6）：203-212.
[6] Tomasetti M，Lee W，Santarelli L，et al. Exosome-derived microRNAs in cancer metabolism： possible implications in cancer diagnostics and therapy [J]. Exp Mol Med，2017， 49（1）：e285.
[7] Pan JH，Zhou H，Zhao XX，et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma： Potential in diagnosis and antitumour treatments （Review） [J]. Int J Mol Med，2018，41（4）：1809-1816.
[8] Hale V，Hale GA，Brown PA，et al. A Review of DNA Methylation and microRNA Expression in Recurrent Pediatric Acute Leukemia [J]. Oncology，2017，92（2）：61-67.
[9] Lee RC，Feinbaum RL，Ambros V，et al. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 [J]. Cell，1993，75（5）：843-854.
[10] Reinhart BJ，Slack FJ，Basson M，et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans [J]. Nature，2000，403（6772）：901-906.
[11] Bam M，Yang X，Sen S，et al. Characterization of Dysregulated miRNA in Peripheral Blood Mononuclear Cells from Ischemic Stroke Patients [J]. Mol Neurobiol，2018， 55（2）：1419-1429.
[12] Schleip R，Wilke J，Schreiner S，et al. Needle biopsy-derived myofascial tissue samples are sufficient for quantification of myofibroblast density [J]. Clin Anat，2018，31（3）：368-372.
[13] Yang C，Xu Y，Cheng F，et al. miR-1301 inhibits hepatocellular carcinoma cell migration，invasion，and angiogenesis by decreasing Wnt/beta-catenin signaling through targeting BCL9 [J]. Cell Death Dis，2017，8（8）：e2999.
[14] Xu B，Xu T，Liu H，et al. MiR-490-5p Suppresses Cell Proliferation and Invasion by Targeting BUB1 in Hepatocellular Carcinoma Cells [J]. Pharmacology，2017，100（5-6）：269-282.
[15] 黄湘俊，张文兴.肝细胞癌中microRNA-888基因家族的表达特征及临床意义[J].临床肝胆病杂志，2019，35（1）：119-122.
[16] Wu XJ，Li Y，Liu D，et al. miR-27a as an oncogenic microRNA of hepatitis B virus- related hepatocellular carcinoma [J]. Asian Pac J Cancer Prev，2013，14（2）：885-889.
[17] Zhang G，Shi J，Yang X，et al. High expression of microRNA-500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation [J]. Oncol Lett，2019，17（6）：5815-5820.
[18] Wen Y，Han J，Chen J，et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma [J]. Int J Cancer，2015，137（7）：1679-1690.
[19] Lai YC，Ushio N，Rahman MM，et al. Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma [J]. Vet Comp Oncol，2018，16（2）：288-296.
[20] Zeng H，Zheng J，Wen S，et al. MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689 [J]. Drug Des Devel Ther，2019，13（10）：435-445.
[21] Wang J，Liang H，Ge H，et al. MicroRNA 363 3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage [J]. Mol Med Rep，2019，19（2）：935-942.
[22] Xu CY，Dong JF，Chen ZQ，et al. MiR-942-3p Promotes the Proliferation and Invasion of Hepatocellular Carcinoma Cells by Targeting MBL2 [J]. Cancer Control，2019，26（1）：1073274819846593.
[23] Yang X，Qu S，Wang L，et al. PTBP3 splicing factor promotes hepatocellular carcinoma by destroying the splicing balance of NEAT1 and pre-miR-612 [J]. Oncogene，2018，37（50）：6399-6413.
[24] Li T，Xie J，Shen C，et al. miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14 [J]. PLoS One，2014，9（12）：e115577.
[25] Zhu Y，Zhou C，He Q. High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma： a pooled analysis [J]. J Int Med Res，2019，47（1）：383-390.